Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Immune Check Point Inhibitors Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Immune Check Point Inhibitors Industry
  • 1.7 COVID-19 Impact: Immune Check Point Inhibitors Market Trends

    • 2 Global Immune Check Point Inhibitors Quarterly Market Size Analysis

    • 2.1 Immune Check Point Inhibitors Business Impact Assessment - COVID-19
      • 2.1.1 Global Immune Check Point Inhibitors Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Immune Check Point Inhibitors Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Immune Check Point Inhibitors Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Immune Check Point Inhibitors Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Immune Check Point Inhibitors Market
    • 3.4 Key Players Immune Check Point Inhibitors Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Immune Check Point Inhibitors Segments, By Type

    • 4.1 Introduction
      • 1.4.1 CLTA-4 Inhibitors
      • 1.4.2 PD-1 & PD-L1 Inhibitor
    • 4.2 By Type, Global Immune Check Point Inhibitors Market Size, 2019-2021

    5 Impact of Covid-19 on Immune Check Point Inhibitors Segments, By Application

    • 5.1 Overview
      • 5.5.1 Lung Cancer
      • 5.5.2 Blood Cancer
      • 5.5.3 Renal Cancer
      • 5.5.4 Bladder Cancer
      • 5.5.5 Melanoma
      • 5.5.6 Hodgkin Lymphoma
    • 5.2 By Application, Global Immune Check Point Inhibitors Market Size, 2019-2021
      • 5.2.1 By Application, Global Immune Check Point Inhibitors Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Bristol-Myers Squibb Company
      • 7.1.1 Bristol-Myers Squibb Company Business Overview
      • 7.1.2 Bristol-Myers Squibb Company Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.1.3 Bristol-Myers Squibb Company Immune Check Point Inhibitors Product Introduction
      • 7.1.4 Bristol-Myers Squibb Company Response to COVID-19 and Related Developments
    • 7.2 AstraZeneca plc
      • 7.2.1 AstraZeneca plc Business Overview
      • 7.2.2 AstraZeneca plc Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.2.3 AstraZeneca plc Immune Check Point Inhibitors Product Introduction
      • 7.2.4 AstraZeneca plc Response to COVID-19 and Related Developments
    • 7.3 Merck & Co
      • 7.3.1 Merck & Co Business Overview
      • 7.3.2 Merck & Co Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.3.3 Merck & Co Immune Check Point Inhibitors Product Introduction
      • 7.3.4 Merck & Co Response to COVID-19 and Related Developments
    • 7.4 Pfizer, Inc
      • 7.4.1 Pfizer, Inc Business Overview
      • 7.4.2 Pfizer, Inc Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.4.3 Pfizer, Inc Immune Check Point Inhibitors Product Introduction
      • 7.4.4 Pfizer, Inc Response to COVID-19 and Related Developments
    • 7.5 F. Hoffmann-La Roche Ltd
      • 7.5.1 F. Hoffmann-La Roche Ltd Business Overview
      • 7.5.2 F. Hoffmann-La Roche Ltd Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.5.3 F. Hoffmann-La Roche Ltd Immune Check Point Inhibitors Product Introduction
      • 7.5.4 F. Hoffmann-La Roche Ltd Response to COVID-19 and Related Developments
    • 7.6 Incyte Corporation
      • 7.6.1 Incyte Corporation Business Overview
      • 7.6.2 Incyte Corporation Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.6.3 Incyte Corporation Immune Check Point Inhibitors Product Introduction
      • 7.6.4 Incyte Corporation Response to COVID-19 and Related Developments
    • 7.7 NewLink Genetics Corporation
      • 7.7.1 NewLink Genetics Corporation Business Overview
      • 7.7.2 NewLink Genetics Corporation Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.7.3 NewLink Genetics Corporation Immune Check Point Inhibitors Product Introduction
      • 7.7.4 NewLink Genetics Corporation Response to COVID-19 and Related Developments
    • 7.8 Celldex Therapeutics, Inc
      • 7.8.1 Celldex Therapeutics, Inc Business Overview
      • 7.8.2 Celldex Therapeutics, Inc Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.8.3 Celldex Therapeutics, Inc Immune Check Point Inhibitors Product Introduction
      • 7.8.4 Celldex Therapeutics, Inc Response to COVID-19 and Related Developments
    • 7.9 GlaxoSmithKline plc
      • 7.9.1 GlaxoSmithKline plc Business Overview
      • 7.9.2 GlaxoSmithKline plc Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.9.3 GlaxoSmithKline plc Immune Check Point Inhibitors Product Introduction
      • 7.9.4 GlaxoSmithKline plc Response to COVID-19 and Related Developments
    • 7.10 Seattle Genetics, Inc.
      • 7.10.1 Seattle Genetics, Inc. Business Overview
      • 7.10.2 Seattle Genetics, Inc. Immune Check Point Inhibitors Quarterly Revenue, 2020
      • 7.10.3 Seattle Genetics, Inc. Immune Check Point Inhibitors Product Introduction
      • 7.10.4 Seattle Genetics, Inc. Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Immune Check Point Inhibitors, including the following market information:
      Global Immune Check Point Inhibitors Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Immune Check Point Inhibitors Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Immune Check Point Inhibitors Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Immune Check Point Inhibitors Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Bristol-Myers Squibb Company, AstraZeneca plc, Merck & Co, Pfizer, Inc, F. Hoffmann-La Roche Ltd, Incyte Corporation, NewLink Genetics Corporation, Celldex Therapeutics, Inc, GlaxoSmithKline plc, Seattle Genetics, Inc., etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      CLTA-4 Inhibitors
      PD-1 & PD-L1 Inhibitor

      Based on the Application:
      Lung Cancer
      Blood Cancer
      Renal Cancer
      Bladder Cancer
      Melanoma
      Hodgkin Lymphoma

      Buy now